ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women’s health - Says subsidiary Inaphaea BioLabs Ltd has made the first customer shipment of its first batch of patient derived cells, which are provided as part of its new range of assay ready reagents. ValiRX says, though the order value is immaterial, it endorses the group’s product offering and potential revenue source. Chief Executive Officer Mark Eccleston says: ‘This first sale of our new product range is a major milestone for our commercialisation efforts.’

Current stock price: 1.69 pence, up 23% in London on Monday afternoon

12-month change: down 84%

Copyright 2024 Alliance News Ltd. All Rights Reserved.